90TEN acquired by Envision Pharma Group
90TEN’s award-winning behavioral science-led communications group will help deliver a deeper and more diversified offering to Envision’s clients, while bringing significant geographical expansion opportunities for the London-based team.
London, UK; 8 April, 2020: Global healthcare communications consultancy 90TEN has been acquired by Envision Pharma Group – a global provider of evidence-based communication services and industry-leading technology solutions.
90TEN will retain its brand and service offering, bringing its insight-led behavioral science model
Feel-Think-Do™ to a broad spectrum of Envision Pharma Group’s communications solutions. This partnership will enrich Envision Pharma Group’s global reach in medical affairs, which include its flagship technology, iEnvision®, together with strategic publications planning and delivery, medical strategy and communications, market access, and creative and digital solutions. In adding 90TEN’s strengths in behavioral science, creativity, and insight-driven communications, this acquisition will deliver an enhanced service offering to the Group’s global client base.
“We’re delighted to welcome an award-winning healthcare communications consultancy into the Envision Pharma Group family,” said David Thompson, CEO, Envision Pharma Group. “90TEN will add its expertise across new verticals for the group – in corporate communications and public relations, while extending Envision’s current footprint in patient engagement and medical communications with its behavioral science methodology. This move bolsters our industry-leading scientific communications capabilities, and enables us to strengthen our offering to clients across the product life cycle.”
“Today marks an exciting milestone in the evolution of 90TEN,” said Paul Tanner, Chairman, 90TEN. “Envision Pharma Group will provide global support to accelerate our plans to extend into more markets and reach more audiences. Both companies share the same values, which is reflected in the similarities between our passionate, ambitious, and collaborative teams who are dedicated to improving patient outcomes.”
Carole North, CEO, 90TEN added, “We’ve always said, if we partnered with another company it would have to be one that was the right strategic and cultural fit for 90TEN, celebrating everything that is 90TEN and the people who make it so successful. Envision Pharma Group embodies all of this and will allow us to retain our individuality, culture, and entrepreneurial spirit as we continue to deliver life-changing communications.”
90TEN will be managed from its London headquarters by the existing management team, including co-founders Paul Tanner and Carole North, and Managing Directors Peter Impey and Alison Doughty.
Based in London, 90TEN employs around 70 members of staff, and works with over half of the top 20 pharma companies in the world serving clients across Europe and North America. The acquisition of 90TEN will bring the total number of Envision Pharma Group employees to around 800 across 14 offices and four continents.
-- Ends --
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and communications. 90TEN provides PR, medical communications, and patient advocacy services that use behavioral science methodologies to maximize brand and health outcomes. 90TEN is one of the leading healthcare communications consultancies in Europe. In 2019, 90TEN was named Communications Consultancy of the Year at the Communiqué Awards; European Agency of the Year at the PR Week Global Awards; Specialist Consultancy of the Year at the PR Week UK Awards; and Support Agency of the Year at the PMEA Awards. To find out more, visit www.90ten.co.uk.
About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision®) that have applicability across many areas of medical affairs and related functional responsibility. Envision Pharma Group provides services and technology solutions to more than 90 companies, including all of the top 20 pharmaceutical companies.
Envision has 14 offices: six in the United Kingdom – Bishop’s Stortford, Glasgow, Horsham, London (Battersea and Hammersmith), and Wilmslow; one in Serbia – Subotica; one in Hungary – Szeged; four in the United States – Fairfield and Glastonbury, CT, Philadelphia, PA, Warren, NJ; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs around 800 team members, including over 250 highly qualified and experienced in-house medical writers, and 190 technology solutions team members who provide software development and customer support. To find out more, visit www.envisionpharmagroup.com.
The acquisition was supported by Envision’s equity partners – Ardian, one of the largest European headquartered private investment funds, and the specialist investor in European healthcare, GHO Capital.
For further information, please contact:
Global Head of Marketing
Envision Pharma Group
Tel: +44 (0)7557 083549
Tel: +44 (0)7900 673376